This study is led by Prof. Kenneth To (School of Pharmacy, The Chinese University of Hong Kong) and Dr. William Cho ...

During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of ...

The global Osimertinib drugs market is on the verge of significant expansion, with an estimated rise in revenue from US$ 4,828.6 million in 2021 to US$ 11,829.8 million by 2027. This growth reflects a ...

Head-to-head comparison data versus osimertinib showed Rybrevant plus Lazcluze significantly extended OS in the first-line treatment of patients with locally advanced or metastatic non-small cell ...

Osimertinib (Tagrisso, AstraZeneca), continues to provide an overall survival (OS) benefit after definitive chemoradiotherapy (CRT) in patients with unresectable stage III epidermal growth factor ...

AstraZeneca Pharma India announced that it has received approval from the Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services, Government of India, to import ...

Kairos Pharma, Ltd. (NYSE American: KAPA) is a clinical stage company involved in treating EGFR-driven lung cancer patients with ENV105 in combination with osimertinib after they fail to respond to ...

PARIS — Final overall survival results from the phase 3 MARIPOSA study showed that the first-line amivantamab plus lazertinib combination extended overall survival notably more than osimertinib ...

Molecular residual disease precedes disease-free survival events in patients receiving osimertinib, placebo; most events occur after osimertinib discontinuation or completion. HealthDay News — For ...

Amivantamab-vmjw plus lazertinib significantly improved OS for certain patients with advanced NSCLC compared with osimertinib. The combination also reduced risk for intracranial progression and ...